
New Market - April 3, 2015
AZ Drug on Swedish Market
AstraZeneca Pharmaceutical’s naloxegol or Moventig, is now available on the Swedish market, the first country in Europe since approval for the European market was granted in 2014. In mid- September 2014, naloxgel was approved for use in the U.S. under the name Movantik. It was launched on the US market this week. Naloxegol is intended […]

Drug Development Pharma - November 19, 2013
Naloxegol reaches milestone
AstraZeneca has announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for naloxegol. The investigational peripherally-acting mu-opioid receptor antagonist (PAMORA) has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, the most common side effect caused by chronic administration of prescription opioid pain […]